Cetuximab is an active treatment of metastatic and chemorefractory thymoma(538 views) Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, Montella L
Frontiers In Bioscience (ISSN: 1093-9946, 1093-4715), 2007 Jan 1; 12(2): 757-761.
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
Department of Pathology, Regina Elena Cancer Institute, Rome, Italy
Diagnostic Imaging and Radiotherapy Department, Federico II University, Naples, Italy
Experimental Pharmacology Unit, Department of Experimental Oncology, National Institute of Tumours, Naples, Italy
References: Not available.
Cetuximab is an active treatment of metastatic and chemorefractory thymoma
Advanced chemorefractory thymic epithelial tumors still represent a challenge in clinical oncology. A rationale-based therapeutic approach targeting a key pathway should represent the ideal solution in a neoplasm that can over-express Epidermal Growth Factor Receptor (EGFR) in the epithelial component. On the basis of these considerations, two patients with metastatic heavily pretreated disease were evaluated for EGFR expression in the primitive tumor, being considered this data as a basis for an anti EGFR treatment with the monoclonal antibody cetuximab which targets EGFR. A strong EGFR expression was revealed by immunohistochemistry in the two cases considered, thus the patients received cetuximab and reported a partial response as assessed by Computed Tomography (CT), Positron Emission Tomography (PET) and fused PET-CT after three months of therapy. Therefore, both patients are still on therapy. This preliminary experience suggests that cetuximab may be a useful therapeutic choice in advanced pre-treated thymic tumors.
Cetuximab is an active treatment of metastatic and chemorefractory thymoma
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(458 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote